| 注册
首页|期刊导航|山东医药|scFv-LAA0融合蛋白的制备及对人肺腺癌细胞H460、小鼠肺腺癌增殖抑制作用观察

scFv-LAA0融合蛋白的制备及对人肺腺癌细胞H460、小鼠肺腺癌增殖抑制作用观察

杨光勇 郭海涛 刘茜明 何光志

山东医药2016,Vol.56Issue(47):4-8,5.
山东医药2016,Vol.56Issue(47):4-8,5.DOI:10.3969/j.issn.1002-266X.2016.47.002

scFv-LAA0融合蛋白的制备及对人肺腺癌细胞H460、小鼠肺腺癌增殖抑制作用观察

Preparation of scFv-LAAO fusion protein and its anti-proliferative effect on human lung adenocarcinoma H460 cells and mouse lung adenocarcinoma cells

杨光勇 1郭海涛 1刘茜明 1何光志1

作者信息

  • 1. 贵阳中医学院,贵阳550002
  • 折叠

摘要

Abstract

Objective To prepare the fusion protein of recombinant anti-interleukin-4 receptor (IL-4R)single anti-body gene and Trimeresurus stejnegeri venom L-amino acid oxidase (LAAO)gene (scFv-LAAO fusion protein),and then to observed its anti-proliferative effect on human lung adenocarcinoma H460 cells and mouse pulmonary adenocarcinoma cells.Methods ① We connected IL-4R scFv gene and LAAO gene to make the scFv-LAAO fusion gene by splicing o-verlapping extension PCR (SOE-PCR),constructed the pET28a-scFv-LAAO recombinant plasmid,and then used the plas-mid to transfect the BL21(DE3)prokaryotic expression bacterium and induced it to express the scFv-LAAO fusion protein. The molecular weight of scFv-LAAO fusion protein was detected by SDS-PAGE,and the expression of His-tag of scFv-LAAO fusion protein was detected by Western blotting.② Setting the control group,cyclophosphamide group and fusion protein group (including high-dose group,medium-dose group and low-dose group),and in the six groups we separately cultured the human lung adenocarcinoma cells H460 with cell culture medium,cyclophosphamide (2.0 mg/mL),and&nbsp;scFv-LAAO fusion protein (4.0,2.0 and 1.0 mg/mL).We detected and calculated the inhibition rates of cell prolifera-tion of the cyclophosphamide group and fusion protein group (high-dose group,medium-dose group and low-dose group)by MTT.Seventy-five mice were selected to establish the animal models of lung adenocarcinoma,and then were randomly di-vided into the control group,cyclophosphamide group and fusion protein group (including high-dose group,medium-dose group and low-dose group),and the six groups were separately given physiological saline,cyclophosphamide (0.1 mL/10g),scFv-LAAO fusion protein (100,50 and 20 mg/kg)through intraperitoneal injection once per day for 10 days.Sev-en days after drug withdrawal,we weighed the mice of each group,calculated the anti-tumor rate of cyclophosphamide group,high-dose group,medium-dose group and low-dose group of fusion protein,at the same time we recorded the surviv-al time of statistics.Results The length of scFv-LAAO fusion gene was 2 000~3 000 bp.After the prokaryotic expression bacterium BL21(DE3)was transfected by the fusion gene,the fusion protein scFv-LAAO was extracted from the superna-tant of bacteria lysate,and its molecular weight was about 86 kD,which coincided with scFv-LAAO fusion protein,and the His-tag of scFv-LAAO fusion protein was detected by Western bloting.No significant difference was found in the cell prolif-eration inhibition rate,anti-tumor rate and survival time of human lung adenocarcinoma H460 cells between the cyclophos-phamide group and high-dose fusion protein group (all P>0.05 ).The cell proliferation inhibition rate,anti-tumor rate and survival time of human lung adenocarcinoma H460 cells of the cyclophosphamide group and high-dose fusion protein group was higher than that of the medium-dose and low-dose fusion protein groups (all P<0.05 ).Meanwhile,the cell proliferation inhibition rate,anti-tumor rate and survival time of the low-dose group was lower than that of the medium-dose group (all P<0.05).Conclusion The scFv-LAAO fusion protein is successfully prepared,and ScFv-LAAO fusion pro-tein can inhibit the proliferation of human lung adenocarcinoma H460 cells and mouse lung adenocarcinoma cells.

关键词

抗白介素4受体单链抗体/竹叶青蛇毒LAAO/白细胞肺肿瘤/肺腺癌/细胞增殖

Key words

anti-interleukin-4 receptor single antibody/Trimeresurus stejnegeri venom L-amino acid oxidase/lung neoplasms/pulmonary adenocarcinoma/cell proliferation

分类

医药卫生

引用本文复制引用

杨光勇,郭海涛,刘茜明,何光志..scFv-LAA0融合蛋白的制备及对人肺腺癌细胞H460、小鼠肺腺癌增殖抑制作用观察[J].山东医药,2016,56(47):4-8,5.

基金项目

贵州省社会发展科技攻关项目(20113020);贵州省科学技术基金资助项目(20122075);贵州省委组织部高层次人才科研条件特助经费资助项目(TZJF201128);贵州省教育厅创新群体重大研究项目(201636)。 ()

山东医药

OA北大核心CSTPCD

1002-266X

访问量0
|
下载量0
段落导航相关论文